GC Cell is accelerating the global expansion of its liver cell carcinoma treatment, Immuncell LC Injection, through technology transfer to Indonesia.
On June 27, GC Cell announced that it has exported its self-produced cell culture media to Indonesia's PT Bifarma Adiluhung (Bifarma).
This export of cell culture media is a follow-up to the technology transfer and license agreement for Immuncell LC Injection signed with Bifarma in September of last year. After the successful completion of the technology transfer in the first half of this year, GC Cell exported five types of cell culture media to Bifarma for local product manufacturing.
Indonesia sees approximately 23,000 new liver cancer patients annually, with around 3,000 of these being post-surgical liver cancer patients who could potentially be candidates for Immuncell LC Injection, indicating strong demand. Starting with this export to Indonesia, GC Cell plans to further strengthen the global presence of Immuncell LC Injection and maximize revenue by expanding exports to other countries.
Meanwhile, Bifarma is a cell therapy-focused subsidiary of KALBE Group, the largest pharmaceutical company in Southeast Asia, and already has a complete local infrastructure for cell therapy production, sales, and logistics. In January, GC Cell and Bifarma successfully held a launch symposium targeting key opinion leaders (KOLs) in Jakarta.
According to a GC Cell representative, "Based on our dedicated production facilities and advanced quality control systems, GC Cell will continue to expand its influence in the global market through the production of high-quality products and achieve sustainable growth."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
